- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03938597
Recruitment Status Recruiting
First Posted May 6, 2019
Last update posted May 13, 2019
It concerns an investigation aiming to investigate genetic biological(s) marker(s) which allow to identify individuals who have risk of serious adverse events to the yellow fever vaccine. This testing is free of hypothesis, because these markers are still unknown. There is no intervention, and it is not possible to establish primary and secondary outcomes.
The rational for the immunological study by LATIM is the observation made by the group that individuals vaccinated with the 17DD yellow fever vaccine show significant alterations on the levels of expression of genes such as CLEC5A, IFNG, IL6, RNASEL, IRF7, IRF9, STAT2 e OAS1 (8). The study which will be conducted by the Rockefeller University will be focused in the qualitative analysis of the genome and exome of volunteers. The study in LATIM will be focused in the quantitative analysis of mRNA, which, together with the results of sequencing, may help in the search for biomarkers. As the expression of mRNA is restricted to the acute phase of the adverse event, it will be done only during the first 30 days after the beginning of the adverse event.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Evidence of a systemic reaction in two or more organs within one month of vaccination
with yellow fever vaccine;
- Laboratory evidence of yellow fever vaccine virus (at least one):
Positive culture for more than 7 days after vaccination; RT-PCR ≥ 3 log10 PFU/mL at any day
after vaccination; Positive RT-PCR more than 14 days after vaccination; Presence of vaccine
virus in tissue by culture, RT-PCR or immunohistochemistry.
- Laboratory exclusion of relevant differential diagnosis such as leptospirosis, viral
hepatitis and arboviruses.
- Cases not obeying these strict criteria but that could be plausibly YEL-AVD or YEL-AND
may be included, if approved by the investigator or co-investigators.
- Cases with adverse event after yellow fever vaccine not severe.
Contact: Emersom C Mesquita, MD, PhD 55 21 3882-7161 email@example.com
Contact: Jean-Laurent Casanova, PhD +1 212 3277332 firstname.lastname@example.org
Assessoria Clinica / Bio-Manguinhos / Fiocruz
Rio De Janeiro
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)